Administering the Bacillus Calmette-Guérin (BCG) vaccine during the active phase of COVID-19 may help protect against the development of long COVID. A phase 3 clinical trial initiated in early ...

ANKTIVA was approved by the FDA in 2024 with BCG for the treatment of BCG unresponsive NMIBC with Papillary tumors with CIS (Cohort A). In the same clinical trial (QUILT-3.032) long term results ...

The authorization was granted to ImmunityBio, the manufacturer of Anktiva ® (nogapendekin alfa inbakicept-pmln), an interleukin-15 receptor agonist, indicated with BCG for adult patients with BCG ...

Bacille Calmette-Guérin (BCG) revaccination didn't help prevent sustained Mycobacterium tuberculosis infection in initially uninfected adolescents without HIV in a randomized trial from South Africa.

Re-induction is now being explored with nadofaragene firadenovec in other trials. “When BCG therapy is ineffective, patients are forced to choose invasive surgery, i.e., total bladder removal ...